New antibiotics are urgently needed to combat rising rates of resistance against all existing classes of antimicrobials. We highlight key issues that complicate the prediction of resistance evolution in the real world and outline the ways in which these can be overcome.
T he rising global rates of antimicrobial resistance against all existing antibiotic classes combined with a near-empty pharmaceutical pipeline for new antibiotic classes have produced renewed urgency in drug discovery efforts 1 . Recent highprofile discoveries based on novel screening methods for natural products (for example, teixobactin 2 ) or modified natural products (such as arylomycin 3 ) are encouraging, but the evolution of resistance remains a serious concern in maintaining the long-term efficacy of new antibiotics. The standard approach for assessing the risk of resistance evolution in such studies is to measure the rate at which spontaneous resistance mutations arise using fluctuation tests: assays in which bacterial cultures are spread onto agar containing an antibiotic, and then the number of colony-forming units (CFU) is compared with that of antibioticfree control cultures 4 . Whole-genome or targeted sequencing of resistant mutants can then identify the mutated genetic locus (or loci) and the degree of resistance provided by different mutations. While these data provide a valuable snapshot of the potential for the tested bacterium to evolve resistance via spontaneous mutation, resistance evolution in the real world is often more complex, as is evident from older antibiotics that induce high rates of in vitro resistance but remain clinically useful (such as rifampicin). Our recent conversations with research scientists in a small antibiotic discovery firm and a multinational pharmaceutical company suggest that the pharmaceutical industry now takes resistance evolution very seriously and implements stringent cut-offs for in vitro resistance mutation frequencies that are deemed acceptable for new antibiotics. An oversimplified view of resistance evolution combined with stringent in vitro targets for resistance risks halting the development of potentially useful compounds if in vitro tests overestimate the evolutionary success of resistant genotypes (by ignoring high in vivo fitness costs, for example). Conversely, underestimating the in vivo evolutionary success of resistant genotypes will lead to wasted efforts in antibiotic development. How, then, can we bridge the gap between existing practice and a more realistic assessment of the risk of resistance evolution to ensure the long-term utility of new antibiotics?
Mind the reality gap
Here we identify four key issues that complicate the prediction of resistance evolution in the real world and outline the ways in which these can be overcome (Fig. 1 In contrast, chronic biofilm infections may sustain large population sizes, lower rates of population turnover and elevated mutation rates, giving rise to high levels of standing genetic variation that are available for natural selection to act upon [9] [10] [11] . Further, physiological tolerance to antibiotics can allow sufficient time for resistance mutations to arise in vivo 12 , which may not be observed in vitro. Improving resistance prediction requires better data on the basic population ecology parameters of different infections. 2. Pre-existing resistance. Standing genetic variation (SGV) for resistance is likely to exist for new antibiotics targeting cellular processes that are already targeted by existing drugs, or that are derived from natural antimicrobials (such as antimicrobial peptides 13 ). For example, S. aureus acquired the staphylococcal cassette chromosome mec (SCCmec) element years before the clinical introduction of methicillin, and methicillin use resulted in the very rapid spread of the Methicillin-resistant S. aureus (MRSA) lineages 14 . Selection by nonantimicrobial drugs 15 and non-clinical antimicrobial agents (like triclosan 16, 17 ) also has the risk of collateral evolution of antibiotic resistance. The vast database of genome sequences of pathogenic bacteria enables genome mining, a powerful method to prospectively test for SGV at genes involved in resistance to new antibiotics. For instance, for arylomycin, seven resistance mutations were identified in the lepB gene 3 . We scanned the European Nucleotide Archive (ENA) for mutations in lepB using the search tool BIGSI 18 (n = 447,833 whole-genome sequence datasets). We found 45,009 datasets contained a lepB gene for which >97% of DNA was identical to the lepB gene in the E. coli strain ATCC 25922, harbouring a total of 98/324 codons with at least one nonsynonymous mutation. We did not detect any of the seven variants that were found to confer arylomycin resistance in the original study comment 82 datasets containing another amino acid substitution at one of those seven positions (p.L142I). This demonstrates that it is feasible to estimate whether resistant variants are circulating among the bacterial population before clinical use of an antibiotic if the mutations that confer resistance are known. Alternatively, resistance determinants against new antibiotics can be detected using functional metagenomics 19 . Here, fragments of metagenomic DNA are expressed and screened for their effect on resistance. This approach is especially useful for detecting unknown resistance genes present in environments where natural-product-derived antibiotics are naturally expressed 20, 21 or in animal or human microbiomes 22, 23 . Pre-existing resistance is especially problematic if these genes become mobilised on mobile genetic elements (MGEs), such as transducing phages and plasmids 24 . Horizontal gene transfer via MGEs or bacteriophages, or via competence for transformation, can strongly contribute to the rise and spread of resistance 25, 26 . Experiments that will estimate rates of gene mobilisation in relevant environments 27 are urgently required. 3. Fitness costs and interplay with the host. Population genetic models suggest that fitness costs associated with resistance limit its persistence upon removal of the antibiotic 5 . Costs arise because resistance mutations may impair the normal function of the target gene or through physiological costs of expressing resistance genes or harbouring MGEs 28 . Fitness costs can be easily quantified using growth or competition assays in lab media and animal infection models, and these should be provided in all reports of new antibiotics 28 . Although there is some degree of agreement between in vivo and in vitro measures of fitness cost 28, 29 , in vitro assays can underestimate the fitness costs of resistance that manifest in more complex infection environments 30 . For example, mutations conferring resistance to bacteriocin-derived avidocin antibiotics cause loss of the surface layer of Clostridium difficile. This has no effect on in vitro growth rate but makes resistant cells highly susceptible to innate immune effectors and avirulent in an in vivo infection model 31 . A high in vitro rate of mutations conferring resistance against a new antibiotic can deter further development of a new drug, even if high fitness costs in vivo effectively limit the success of these resistant mutants in patients because of competition or immune clearance. For example, the development of mecillinam would currently be halted by pharmaceutical companies because of high resistance mutation frequencies (ranging from 8 × 10 −8 to 2 × 10 −5 mutations per cell), but resistance in the clinic is rare because of the low in vivo fitness of mutants 32 . Accurately modelling within-host bacterial metabolism and physiology by using more realistic experimental environments, such as host-mimicking media 33, 34 , in vitro biofilm models 35, 36 , animal models 37 or ex vivo tissue models 38, 39 , will offer a more accurate picture of fitness costs. 4. Compensatory evolution. Over time, second-site mutations that compensate for the fitness cost of the resistance mutation while leaving the resistant phenotype intact can allow persistence of resistant genotypes in vivo and in environmental reservoirs in the absence of antibiotic selection 28, 40 . The targets of compensatory mutations can be determined using evolveand-resequence experiments in which resistant mutants are serially passaged without antibiotic until they recover ancestral-level fitness [41] [42] [43] . For example, mutations in Mycobacterium tuberculosis that compensate for the fitness cost of rifampicin resistance in vitro are found in clinical isolates and contribute to the tuberculosis epidemic 44 . The extent to which lab studies provide an unbiased view of compensatory evolution in the real world is unclear 45 , but one promising solution to this problem is to use genome-wide association analyses of bacterial genomic datasets to link known resistance mutations with subsequent compensatory mutations. For example, acquisition of multidrug resistance plasmids in E. coli sequence type 131 has been shown to be associated with specific regulatory mutations that may compensate the fitness cost of plasmid carriage 46 .
Bridging the gap
Ideally, evolutionary analysis of resistance should accompany in vivo experimental and clinical trials of new antibiotics. The following changes to existing practices would allow far better understanding of the potential for resistance evolution:
• Appropriate choice of infection models during research and development. Consideration of the physicochemical environment at infection sites and its effects on bacterial growth, gene expression and physiology will provide better estimates of likely rates of resistance emergence and associated fitness costs, which may differ substantially from those observed in standard laboratory growth media 34 . For example, the leucyl-tRNA synthetase inhibitor GSK2251052 showed limited resistance development in vitro but failed in clinical trials because of rapid emergence of resistance in treated . Improved estimates of the risk of in vivo resistance would allow drug candidates to be better prioritised for progression to clinical trials and could therefore directly benefit the pharmaceutical industry by enabling more effective targeting of resource investment during antibiotic development.
• Dosing to minimise resistance selection.
Massive experimental and modelling efforts are made to quantify the pharmacokinetics/pharmacodynamics (PK/PD) of new antibiotics before a clinical trial, with the goal of maximizing antibiotic efficacy. Minimizing selection for resistance should also be a goal of PK/PD studies 48 , which should employ appropriate infection models.
• More intensive sampling of infections during clinical trials. Current approaches sample single colonies, ignoring the diversity present in most infections and therefore losing the opportunity to understand evolutionary processes occurring in infections 49, 50 . More extensive culture-based sampling should be combined with deep sequencing to quantify resistance allele frequencies and capture hard-to-culture organisms (such as persister cells and polymicrobial infections). Providing access for scientists to the samples from completed clinical trials would allow the development of methods and analyses for efficiently characterizing the evolutionary mechanisms leading to resistance in patients. Furthermore, development of culture conditions that allow maintenance of diverse bacterial populations and/or communities in the lab would facilitate understanding of how resistance evolution is a function of microbial community interactions.
• Microbiome sampling in clinical trials.
Antibiotic treatment often has collateral effects on the microbiome, including driving lateral transfer of resistance elements at other body sites 51 . Combining new bioinformatics tools for resistance prediction 52 with long-read or proximity-ligation sequencing technologies allows localisation of resistance genes to their genomic context and the tracking of gene mobilisation and transfer 53, 54 .
These new approaches will increase the scale and cost of clinical trials in the immediate term and will require that medical funders and pharmaceutical companies embrace eco-evolutionary thinking. However, there are likely to be direct benefits in terms of more effective targeting of investment and fewer potentially useful drug candidates being discarded owing to misleading in vitro resistance estimates. It is therefore possible that taking a more realistic view of resistance evolution could help rejuvenate the antibiotic pipeline. 
